Quarterly ResultMay 7, 2026, 07:08 AM
Amylyx Q1 Net Loss $41.3M; Avexitide Phase 3 Data Q3 2026
AI Summary
Amylyx Pharmaceuticals reported a net loss of $41.3 million, or $0.37 per share, for the first quarter ended March 31, 2026, compared to a net loss of $35.9 million, or $0.42 per share, in the prior year. The company announced that topline data from the pivotal Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia (PBH) is on track for Q3 2026, with potential commercial launch in 2027 if approved. Amylyx also confirmed a cash runway extending into 2028, supporting operations through potential avexitide commercialization. Additionally, enrollment was completed for the LUCIDITY trial and Cohort 2 of the Phase 1 LUMINA trial for AMX0114 in ALS.
Key Highlights
- Q1 2026 net loss was $41.3 million, or $0.37 per share, compared to $35.9 million, or $0.42 per share, in Q1 2025.
- Research and development expenses increased to $27.6 million in Q1 2026 from $22.1 million in Q1 2025.
- Selling, general, and administrative expenses rose to $16.2 million in Q1 2026 from $15.7 million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $279.8 million as of March 31, 2026.
- Cash runway is expected to extend into 2028, funding operations through potential avexitide commercialization.
- Topline data from Phase 3 LUCIDITY trial of avexitide in PBH is anticipated in Q3 2026.
- Enrollment completed for Phase 3 LUCIDITY trial (78 participants) and Cohort 2 of Phase 1 LUMINA trial (12 participants).
- Initiated Expanded Access Program for avexitide in PBH in May 2026.